Study suggests ZCB11 as a promising antibody drug against all SARS-CoV-2 variants of concern

By | July 13, 2022
Researchers at the AIDS Institute, The University of Hong Kong, Department of Microbiology, School of Clinical Medicine, the LKS Faculty of Medicine of The University of Hong Kong and the State Key Laboratory of Emerging Infectious Diseases, HKU, together with structural biologists at The Hong Kong University of Science and Technology, have demonstrated that ZCB11, a broadly neutralizing antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2.